Department of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China; Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Department of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
J Ethnopharmacol. 2020 Mar 1;249:112371. doi: 10.1016/j.jep.2019.112371. Epub 2019 Nov 1.
Bushen Tiansui Formula (BSTSF) is a traditional Chinese medicine formula used clinically to treat Alzheimer's disease (AD) for many years. Previously, we have partially elucidated the mechanisms involved in the therapeutic effects of BSTSF on AD. However, the underlying mechanisms remain largely unclear.
The aim of this study was to further investigate the therapeutic effects of BSTSF on AD using an integrated strategy of network pharmacology and serum metabolomics.
The rat models of AD were established using Aβ 1-42 injection, and morris water maze test was used to evaluate the efficacy of BSTSF on AD. Next, network pharmacology analysis was applied to identify the active compounds and target genes, which might be responsible for the effect of BSTSF. Then, a metabolomics strategy has been developed to find the possible significant serum metabolites and metabolic pathway induced by BSTSF. Additionally, two parts of the results were integrated to confirm each other.
The results of the network pharmacology analysis showed 37 compounds and 64 potential target genes related to the treatment of AD with BSTSF. The functional enrichment analysis indicated that the potential mechanism was mainly associated with the tumor necrosis factor signaling pathway and phosphatidylinositol 3 kinase/protein kinase B signaling pathway. Based on metabolomics, 78 differential endogenous metabolites were identified as potential biomarkers related to the BSTSF for treating AD. These metabolites were mainly involved in the relevant pathways of linoleic acid metabolism, α-linolenic acid metabolism, glycerophospholipid metabolism, tryptophan metabolism, and arginine and proline metabolism. These findings were partly consistent with the findings of the network pharmacology analysis.
In conclusion, our results solidly supported and enhanced out current understanding of the therapeutic effects of BSTSF on AD. Meanwhile, our work revealed that the proposed network pharmacology-integrated metabolomics strategy was a powerful means for identifying active components and mechanisms contributing to the pharmacological effects of traditional Chinese medicine.
补肾填髓方(BSTSF)是一种传统的中药配方,临床上用于治疗阿尔茨海默病(AD)已有多年。此前,我们已经部分阐明了 BSTSF 治疗 AD 的治疗效果所涉及的机制。然而,其潜在的机制在很大程度上仍不清楚。
本研究旨在通过网络药理学和血清代谢组学的综合策略,进一步研究 BSTSF 对 AD 的治疗作用。
采用 Aβ1-42 注射建立 AD 大鼠模型,采用 Morris 水迷宫试验评价 BSTSF 对 AD 的疗效。接下来,应用网络药理学分析方法,鉴定可能与 BSTSF 作用相关的活性化合物和靶基因。然后,建立了代谢组学策略,以寻找 BSTSF 可能引起的潜在显著血清代谢物和代谢途径。此外,将两部分结果整合以相互确认。
网络药理学分析结果显示,37 种化合物和 64 个与 BSTSF 治疗 AD 相关的潜在靶基因。功能富集分析表明,潜在的作用机制主要与肿瘤坏死因子信号通路和磷脂酰肌醇 3 激酶/蛋白激酶 B 信号通路有关。基于代谢组学,共鉴定出 78 种差异内源性代谢物作为与 BSTSF 治疗 AD 相关的潜在生物标志物。这些代谢物主要涉及亚麻酸代谢、α-亚麻酸代谢、甘油磷脂代谢、色氨酸代谢和精氨酸和脯氨酸代谢相关通路。这些发现与网络药理学分析的结果部分一致。
总之,我们的研究结果为 BSTSF 治疗 AD 的治疗效果提供了有力的支持和补充,同时也表明所提出的网络药理学-整合代谢组学策略是一种识别中药发挥药理作用的活性成分和机制的有效手段。